EXPERIENCE WITH USING NUTRICOMP® ADN BRAUN RENAL IN NUTRITION MAINTENANCE OF PATIENTS ON REGULAR HEMODIALYSIS

THE AIM of the investigation was to sum up the authors’ personal experience with using Nutricomp® ADN Braun Renal (B/Braun, Germany) in practice of nutrition maintenance of patients on regular hemodialysis (HD). PATIENTS AND METHODS. Under examination there was a group of 20 patients (12 men and 8 women) treated by regular HD and having symptoms of protein-energetic insufficiency (PEI). The patients were given daily doses of the drug (45g a day). The laboratory and anthropometrical indices characterizing the presence and degree of PEI were studied in dynamics. The observations were carried out during 6-12 months. RESULTS. It was found that the postdialysis body mass grew clearly greater by the end of observations (from 62.8±13.3 to 64.2±13.5 kg; p<0.002) ; body mass index from 21.5 ±3.20 to 22.0±3.36 kg/m2; p< 0.001); shoulder circumference (from 22.92± 3.41 to 23.51±3.50 cm; p<0.001); circumference of the shoulder muscles (from 21.02 ±4.06 to 28.39±3.34 cm; p<0.001); thickness of the skin-fat fold over triangularis and biceps (from 6.11±4.70 to 6.87±4.94 mm; p<0.02) as well as the absolute content of lymphocytes in peripheral blood (from 1.0±0.36 to 1.63±0.54 х 109/l; p<0.001). The predialysis level of total calcium in blood serum (from 2.42±0.28 to 2.25±0.15 mmol/l; p<0.02) became reliably lower. No reliable changes were found in other laboratory parameters under study such as concentration of albumin in blood serum, of inorganic phosphorus, total cholesterol, content of hemoglobin and erythrocytes in peripheral blood. On the whole, an analysis of the degree of malnutrition has shown that its symptoms disappeared in 3 patients, its degree became less in 16 patients and only in 1 patient the PEI became more severe. CONCLUSION. Our experience with using Nutricomp® ADN Braun Renal in patients with the terminal stage of renal failure treated by regular hemodialysis shows good perspectives of this drug as an additional enteral nutrition.

1. Кучер АГ. Проблемы лечебного питания у больных с хронической почечной недостаточностью. Нефрология 1997; 1(1): 39-46

2. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995; 6(5): 1329-1341

3. Lim VS, Kopple JD. Protein metabolism in patients in chronic renal failure: role of uremia and dialysis. Kidney Int 2000: 58(1)): 1-10

4. Cretow GM, Ling J, Lew JM et al. The association of intradialytic parenteral nutrition administration with survival in hemodialysis patients. Am J Kidney Dis 1994; 24(6): 912-920

5. Hakim RM, Lewin M. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21: 125-137

6. Bossola M, Muscaritoli M, Tazza L et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005 46(3):371-386

7. Григорьева НД, Кучер АГ. Влияние длительного приема соевого изолята «Supro – 760» на антропометрические показатели больгных, получающих лечение хроническим гемодиализом. Нефрология 2004; 8(1): 42-50

8. Chen ST, Chen JR, Yang CS et al. Effect of soya protein on serum lipid profile and lipoprotein concentrations in patients undergoing hypercholesterolaemic haemodialysis. Br J Nut. 2006; 95(2):366-371

9. Cano NJ, Saingra Y, Dupuy AM et al. Intradialytic parenteral nutrition: comparison of olive oil versus soybean oil-based lipid emulsions. Br J Nutr 2006; 95(1):152-159

10. Dwyer JT, Larive B, Leung J et al. HEMO Study Group. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study. Kidney Int 2005: 68(4):1766-1776